[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3375 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 3375

  To establish programs to address addiction and overdoses caused by 
      illicit fentanyl and other opioids, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 16, 2023

Ms. Kuster (for herself, Ms. Blunt Rochester, Mr. Bacon, Mr. Tonko, Mr. 
Trone, Mr. Panetta, Mrs. Trahan, Mr. Allred, Ms. Craig, Ms. Pettersen, 
 Ms. Barragan, and Mr. Norcross) introduced the following bill; which 
 was referred to the Committee on Energy and Commerce, and in addition 
  to the Committee on the Judiciary, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
  To establish programs to address addiction and overdoses caused by 
      illicit fentanyl and other opioids, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE; TABLE OF CONTENTS.

    (a) Short Title.--This Act may be cited as the ``Support, 
Treatment, and Overdoses Prevention of Fentanyl Overdoses Act of 2023'' 
or the ``STOP Fentanyl Overdoses Act of 2023''.
    (b) Table of Contents.--The table of contents for this Act is as 
follows:

Sec. 1. Short title; table of contents.
Sec. 2. Definitions.
                TITLE I--IMPROVING FENTANYL SURVEILLANCE

Sec. 101. Enhanced drug surveillance.
Sec. 102. Collection of overdose data.
Sec. 103. Public health support for law enforcement.
Sec. 104. Fentanyl detection.
Sec. 105. Grants to improve public health surveillance in forensic 
                            laboratories.
               TITLE II--STEMMING THE SUPPLY OF FENTANYL

Sec. 201. Report on countries that produce synthetic drugs.
Sec. 202. GAO report on international mail and cargo screening.
  TITLE III--OVERDOSE PREVENTION AND SUBSTANCE USE DISORDER TREATMENT 
                                PROGRAMS

Sec. 301. Opioid treatment education.
Sec. 302. Study on naloxone access.
Sec. 303. Increasing access to medication for opioid overdose reversal.
Sec. 304. Grant program on harms of drug misuse.
Sec. 305. Good Samaritan immunity.
Sec. 306. Report on overdose prevention centers.
Sec. 307. Prisons and substance use disorder treatment.

SEC. 2. DEFINITIONS.

    In this Act, except as otherwise provided:
            (1) The term ``Assistant Secretary'' means the Assistant 
        Secretary for Mental Health and Substance Use.
            (2) The term ``Secretary'' means the Secretary of Health 
        and Human Services.
            (3) The term ``fentanyl-related substance'' has the meaning 
        given the term in section 1308.11(h)(30)(i) of title 21, Code 
        of Federal Regulations (or successor regulations).

                TITLE I--IMPROVING FENTANYL SURVEILLANCE

SEC. 101. ENHANCED DRUG SURVEILLANCE.

    (a) CDC Surveillance Program.--Title III of the Public Health 
Service Act (42 U.S.C. 241 et seq.) is amended by inserting after 
section 317V of such Act (42 U.S.C. 247b-24) the following:

``SEC. 317W. ENHANCED DRUG SURVEILLANCE.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall enhance the 
Overdose Data to Action drug surveillance program of the Centers and 
other drug surveillance programs by--
            ``(1) encouraging States, political subdivisions of States, 
        and territories to participate;
            ``(2) increasing and accelerating the collection of data on 
        fentanyl, fentanyl-related substances, other synthetic opioids, 
        and new emerging drugs of use (including harmful adulterants of 
        fentanyl such as xylazine), including the collection of related 
        overdose data from medical examiners and drug treatment 
        admissions and information regarding drug seizures; and
            ``(3) utilizing available and emerging information on 
        fentanyl, fentanyl-related substances, other synthetic opioids, 
        and new emerging drugs of abuse, including information from--
                    ``(A) the High Intensity Drug Trafficking Areas 
                program;
                    ``(B) the National Drug Early Warning System;
                    ``(C) State and local public health authorities;
                    ``(D) Federal, State, and local public health 
                laboratories; and
                    ``(E) drug seizures by Federal, State, and local 
                law enforcement agencies, including information from 
                the National Seizure System and the National Forensic 
                Laboratory Information System of the Drug Enforcement 
                Administration.
    ``(b) Information Sharing.--The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention, shall 
publicly disseminate findings collected through the Overdose Data to 
Action drug surveillance program of the Centers for Disease Control and 
Prevention.
    ``(c) Definition.--In this section, the term `fentanyl-related 
substance' has the meaning given the term in section 1308.11(h)(30)(i) 
of title 21, Code of Federal Regulations (or successor regulations).''.
    (b) Law Enforcement Reporting.--Each Federal law enforcement agency 
shall report information on all drug seizures by that agency to the 
Drug Enforcement Administration for inclusion in the National Seizure 
System.
    (c) GAO Report.--Not later than 2 years after the date of enactment 
of this Act, the Comptroller General of the United States shall--
            (1) publish a report analyzing how Federal agencies can 
        improve their collection, reporting, sharing, and analytic use 
        of drug seizure data across Federal agencies and with State and 
        local governments; and
            (2) include in such report an analysis of how well 
        available data on drug seizures can measure progress toward 
        reducing drug trafficking into and within the country, as 
        outlined in strategies such as the National Drug Control 
        Strategy of the Office of National Drug Control Policy.

SEC. 102. COLLECTION OF OVERDOSE DATA.

    (a) In General.--Not later than 2 years after the date of enactment 
of this Act, the Secretary shall commence a study on how to most 
efficiently track overdoses by type of drug, including fentanyl.
    (b) Grant Program.--
            (1) In general.--Upon completion of the study under 
        subsection (a), and taking into consideration the results of 
        such study, the Secretary shall award grants to States to 
        facilitate the collection of data with respect to fentanyl-
        involved overdoses.
            (2) Requirement.--As a condition on receipt of a grant 
        under this subsection, an applicant shall agree to share the 
        data collected pursuant to the grant with the Centers for 
        Disease Control and Prevention.
            (3) Preference.--In awarding grants under this subsection, 
        the Secretary shall give preference to applicants whose grant 
        proposals demonstrate the greatest need for collecting timely 
        and accurate data on overdoses.

SEC. 103. PUBLIC HEALTH SUPPORT FOR LAW ENFORCEMENT.

    (a) Support for Fentanyl Detection and Handling.--The Secretary, in 
consultation with the Attorney General, shall carry out a program to 
provide to Federal, State, and local law enforcement agencies training 
on accurate information about fentanyl and how to detect and handle 
fentanyl.
    (b) Evidence-Based.--The program under subsection (a) shall comply 
with evidence-based guidelines, including the ``Fentanyl Safety 
Recommendations for First Responders'' (or any successor guidelines) of 
the Office of National Drug Control Policy.

SEC. 104. FENTANYL DETECTION.

    (a) Testing of Contaminants.--The Secretary, acting through the 
Assistant Secretary and in coordination with the Director of the 
Centers for Disease Control and Prevention, shall continue to improve 
efforts to enhance screening and identification of contaminants in 
drugs to prevent overdoses.
    (b) Research Into Technologies.--The Secretary shall conduct or 
support research for the development or improvement of portable and 
affordable technologies related to checking drugs for fentanyl and 
fentanyl-related substances, including chemical screening device 
methods.

SEC. 105. GRANTS TO IMPROVE PUBLIC HEALTH SURVEILLANCE IN FORENSIC 
              LABORATORIES.

    Title I of the Omnibus Crime Control and Safe Streets Act of 1968 
(34 U.S.C. 10101 et seq.) is amended by adding at the end the 
following:

  ``PART PP--CONFRONTING THE USE OF HEROIN, FENTANYL, AND ASSOCIATED 
                            SYNTHETIC DRUGS

``SEC. 3061. GRANTS TO ADDRESS PUBLIC SAFETY THROUGH IMPROVED FORENSIC 
              LABORATORY DATA.

    ``(a) Purpose.--The purpose of a grant awarded under this section 
shall be to promote public health by assisting a State or unit of local 
government--
            ``(1) establish or improve a surveillance program in order 
        to facilitate the seizure of covered controlled substances; and
            ``(2) carry out the activities described in section 101 of 
        the STOP Fentanyl Overdoses Act of 2023.
    ``(b) Establishment of Grant.--The Attorney General, acting through 
the Director of the Bureau of Justice Assistance, may make a grant to a 
State or unit of local government to promote public health by 
establishing or improving a surveillance program in order to facilitate 
the seizure of covered controlled substances.
    ``(c) Eligible Projects.-- A grant awarded under this section shall 
be used for a program, project, or other activity to--
            ``(1) reimburse a State, local, or other forensic science 
        laboratory for costs associated with testing to help address 
        any backlog of untested samples of covered controlled 
        substances;
            ``(2) reimburse a State, local, or other forensic science 
        laboratory for the procurement of equipment, technology, or 
        other support systems;
            ``(3) reimburse State, local, or other forensic science 
        laboratory for improved, real time data exchange with the 
        Centers for Disease Control and Prevention on covered 
        controlled substances; and
            ``(4) support a State or local health departments deployed 
        to address the use of covered controlled substances.
    ``(d) Additional Requirement.--A program, project, or other 
activity pursuant to subsection (c)(2) shall require that the State, 
unit of local government, or Tribe demonstrate, to the satisfaction of 
the Attorney General, that any reimbursement would result in improved 
efficiency of laboratory testing and help prevent future backlogs.
    ``(e) Allocation.--
            ``(1) Population allocation.--Seventy-five percent of the 
        amount made available to carry out this section in a fiscal 
        year shall be allocated to each State or unit of local 
        government that meets the requirements of section 2802 so that 
        each State or unit of local government shall receive an amount 
        that bears the same ratio to the 75 percent of the total amount 
        made available to carry out this section for that fiscal year 
        as the population of the State or unit of local government 
        bears to the population of all States or units of local 
        governments.
            ``(2) Discretionary allocation.--Twenty-five percent of the 
        amount made available to carry out this section in a fiscal 
        year shall be allocated pursuant to the discretion of the 
        Attorney General for competitive grants to States or units of 
        local government with high rates of primary treatment 
        admissions for polysubstance use, including for covered 
        controlled substances, for use by State, local, or Tribal law 
        enforcement agencies.
            ``(3) Limitation.--Not less than 60 percent of any amounts 
        made available to carry out this section shall be awarded for a 
        program, project, or other activity under paragraph (1) or (2) 
        of subsection (c).
            ``(4) Minimum requirement.--Notwithstanding paragraphs (1), 
        (2), and (3), each State receiving funds shall not receive less 
        than 0.6 percent of the amount made available to carry out this 
        section in each fiscal year.
    ``(f) Covered Controlled Substance Defined.--In this section, the 
term `covered controlled substance' means heroin, fentanyl, a fentanyl-
related substance, and any associated synthetic drug.''.

               TITLE II--STEMMING THE SUPPLY OF FENTANYL

SEC. 201. REPORT ON COUNTRIES THAT PRODUCE SYNTHETIC DRUGS.

     Not later than one year after the date of enactment of this Act, 
the Secretary of State shall submit to the Committee on Energy and 
Commerce of the House of Representatives and the Committee on the 
Judiciary of the Senate a report--
            (1) identifying the countries the Secretary determines are 
        the principal producers of synthetic drugs trafficked into the 
        United States;
            (2) assessing how and why those countries are producing 
        such drugs; and
            (3) describing measures the Secretary plans to take to 
        reduce the flow of such drugs into the United States.

SEC. 202. GAO REPORT ON INTERNATIONAL MAIL AND CARGO SCREENING.

    Not later than one year after the date of enactment of this Act, 
the Comptroller General of the United States shall submit to the 
Congress a report reviewing the impact of High Intensity Drug 
Trafficking Areas program on illicit fentanyl and fentanyl-related 
substances imported through international mail and cargo, including 
discussion of the following:
            (1) The volume of fentanyl and fentanyl-related substances 
        being imported into the country by means of international mail 
        and cargo.
            (2) The potential impact of increased screening for illicit 
        fentanyl and fentanyl-related substances on--
                    (A) deterring drug trafficking in the United 
                States;
                    (B) interdicting fentanyl and fentanyl-related 
                substances that were manufactured outside of the United 
                States and intended, or attempted, to be imported into 
                the United States;
                    (C) the number of Federal criminal prosecutions 
                based on the manufacture, distribution, or possession 
                of fentanyl or fentanyl-related substances, 
                disaggregated by demographic data, including sex, race, 
                and ethnicity, of the offender;
                    (D) the charges brought in such prosecutions;
                    (E) the impacts of prosecutions on reducing demand 
                and availability to users; and
                    (F) the development of new fentanyl-related 
                substances.
            (3) The need for non-invasive technology in screening for 
        fentanyl and fentanyl-related substances, taking into account 
        the findings pursuant to paragraphs (1) and (2).

  TITLE III--OVERDOSE PREVENTION AND SUBSTANCE USE DISORDER TREATMENT 
                                PROGRAMS

SEC. 301. OPIOID TREATMENT EDUCATION.

    Part D of title V of the Public Health Service Act (42 U.S.C. 290dd 
et seq.) is amended by adding at the end the following:

``SEC. 553. OPIOID TREATMENT EDUCATION.

    ``(a) In General.--The Secretary shall award grants to States and 
local governmental entities to provide education to stakeholders, 
including health care providers, criminal justice professionals, and 
substance use disorder treatment personnel, on the current state of 
research on treatment for opioid use disorder, including--
            ``(1) the use of opioid agonists or partial agonists; and
            ``(2) the potential benefits of the use of opioid agonists 
        or partial agonists for affected individuals.
    ``(b) Report.--Not later than one year after the date of enactment 
of the STOP Fentanyl Overdoses Act of 2023, the Secretary shall submit 
a report to the Committee on Energy and Commerce of the House of 
Representatives and the Committee on Health, Education, Labor, and 
Pensions of the Senate, including the following data:
            ``(1) The number of people reached by educational materials 
        funded pursuant to this section.
            ``(2) The geographic areas where people received such 
        educational materials.
            ``(3) The remaining populations and areas targeted for 
        awareness of educational materials, including the 
        characteristics of such populations and areas such as the type 
        of stakeholder and geographic area.
            ``(4) The select outcomes of education funded pursuant to 
        this section as determined by the Secretary.''.

SEC. 302. STUDY ON NALOXONE ACCESS.

    (a) In General.--The Comptroller General of the United States shall 
conduct a study on actions that may be taken to ensure appropriate 
access and affordability of naloxone for individuals seeking to 
purchase naloxone. Such study shall address what is known about--
            (1) coverage of naloxone (in any available form), including 
        whether naloxone can be covered as an over-the-counter drug 
        under a group health plan or group or individual health 
        insurance coverage (as such terms are defined in section 2791 
        of the Public Health Service Act (42 U.S.C. 300gg-91)) or for 
        individuals entitled to benefits under part A or enrolled under 
        part B of title XVIII of the Social Security Act (42 U.S.C. 
        1395 et seq.) or receiving medical assistance under a State 
        plan under title XIX of such Act (42 U.S.C. 1396 et seq.) or a 
        waiver of such plan;
            (2) the out-of-pocket cost to consumers purchasing 
        naloxone--
                    (A) with a prescription, with and without coverage 
                under any such plan or coverage;
                    (B) over-the-counter, with and without coverage 
                under any such plan or coverage; and
                    (C) pursuant to a standing order; and
            (3) other factors impacting coverage, including barriers in 
        covering naloxone as an over-the-counter drug, the relative net 
        costs of naloxone when purchased over-the-counter without 
        insurance coverage compared to when purchased with a 
        prescription and covered under a group health plan or health 
        insurance coverage, and the availability of naloxone purchased 
        and distributed through public health entities.
    (b) Report.--Not later than 2 years after the date of the enactment 
of this Act, the Comptroller General of the United States shall submit 
to Congress a report that contains the findings of the study conducted 
under subsection (a).

SEC. 303. INCREASING ACCESS TO MEDICATION FOR OPIOID OVERDOSE REVERSAL.

    (a) Transactions.--Section 581(24)(B) of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 360eee(24)(B)) is amended--
            (1) by redesignating clauses (xvii) and (xviii) as clauses 
        (xviii) and (xix), respectively; and
            (2) by inserting after clause (xvi) the following:
                            ``(xvii) the distribution of an opioid 
                        antagonist indicated for emergency treatment of 
                        opioid overdose, such as naloxone, by or to an 
                        overdose prevention, syringe services program, 
                        or other harm reduction service;''.
    (b) Wholesale Distribution.--Section 503(e)(4) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 353(e)(4)) is amended--
            (1) by redesignating subparagraphs (R) and (S) as 
        subparagraphs (S) and (T), respectively; and
            (2) by inserting after subparagraph (Q) the following:
                    ``(R) the distribution of an opioid antagonist 
                indicated for emergency treatment of opioid overdose, 
                such as naloxone, by or to an overdose prevention, 
                syringe services program, or other harm reduction 
                service;''.

SEC. 304. GRANT PROGRAM ON HARMS OF DRUG MISUSE.

    Part D of title V of the Public Health Service Act (42 U.S.C. 290dd 
et seq.), as amended by section 301, is further amended by adding at 
the end the following:

``SEC. 554. GRANT PROGRAM ON HARMS OF DRUG MISUSE.

    ``(a) In General.--The Assistant Secretary, in consultation with 
the Director of the Centers for Disease Control and Prevention, shall 
award grants to States and political subdivisions of States to support 
the delivery of overdose prevention services, including distribution of 
Food and Drug Administration-approved opioid reversal agents such as 
naloxone, fentanyl strips, and other harm reduction services that 
address the harms of drug misuse, including by--
            ``(1) connecting individuals at risk for, or with, a 
        substance use disorder to overdose education, counseling, and 
        health education; and
            ``(2) encouraging such individuals to take steps to reduce 
        the harms associated with substance misuse.
    ``(b) Considerations.--In awarding grants under this section, the 
Assistant Secretary shall prioritize grants to applicants that are--
            ``(1) organizations providing culturally competent care in 
        terms of considerations based on race, language, ethnicity, 
        gender, sexuality, or disability; or
            ``(2) proposing to serve areas with--
                    ``(A) a higher proportion of the population who 
                meet criteria for dependence on, or abuse of, illicit 
                drugs;
                    ``(B) a higher drug overdose death rate; and
                    ``(C) a greater behavioral health and substance use 
                disorder workforce need.
    ``(c) Special Considerations.--A recipient of a grant under this 
section for the purposes described in subsection (a)(2) shall provide 
overdose prevention services, as follows:
            ``(1) Ensure that not less than 60 percent of the grant 
        funds are used for harm reduction programs.
            ``(2) Prioritize the delivery of opioid antagonists to--
                    ``(A) people who use opioids or illicit drugs;
                    ``(B) families of such people;
                    ``(C) first responders such as law enforcement 
                personnel and nonemergency services such as fire 
                fighters and park rangers; and
                    ``(D) community service providers, such as library, 
                school, and public transportation personnel.
    ``(d) Use of Grant Awards.--A recipient of a grant under this 
section may use grant funds for the following:
            ``(1) Adapting, maintaining, and expanding essential 
        services provided by harm reduction service organizations to 
        address the risks of drug overdose and contraction of 
        infectious disease.
            ``(2) Maintaining or hiring staff.
            ``(3) Supporting program operational costs, including 
        staff, rent, and vehicle purchase or maintenance.
            ``(4) Program supplies.
            ``(5) Support and case management services.''.

SEC. 305. GOOD SAMARITAN IMMUNITY.

    (a) In General.--Part B of title II of the Public Health Service 
Act is amended by inserting after section 248 of such Act (42 U.S.C. 
238q) the following:

``SEC. 249. GOOD SAMARITAN IMMUNITY.

    ``(a) Limitation on Civil Liability for Individuals Who Administer 
Opioid Overdose Reversal Drugs.--
            ``(1) In general.--Notwithstanding any other provision of 
        law, except as provided in paragraph (2), no individual shall 
        be liable in any Federal or State proceeding for harm caused by 
        the emergency administration of an opioid overdose reversal 
        drug to an individual who has or reasonably appears to have 
        suffered an overdose from heroin or another opioid, if the 
        individual who administers the opioid overdose reversal drug 
        does so in good faith.
            ``(2) Exception.--Paragraph (1) shall not apply to an 
        individual if the harm was caused by the gross negligence or 
        reckless misconduct of the individual who administers the drug.
            ``(3) Definitions.--In this subsection:
                    ``(A) The term `health care professional' means a 
                person licensed by a State to prescribe prescription 
                drugs.
                    ``(B) The term `opioid overdose reversal drug' 
                means a drug approved under section 505 of the Federal 
                Food, Drug, and Cosmetic Act that is indicated for the 
                partial or complete reversal of the pharmacological 
                effects of an opioid overdose in the human body.
                    ``(C) The term `opioid overdose prevention program' 
                means a program operated by a local health department, 
                harm reduction or other community-based organization, 
                substance abuse treatment organization, law enforcement 
                agency, fire department, other first responder 
                department, or voluntary association, or a program 
                funded by a Federal, State, or local government, that 
                works to prevent opioid overdoses by in part providing 
                opioid overdose reversal drugs and education--
                            ``(i) to individuals at risk of 
                        experiencing an opioid overdose; or
                            ``(ii) to an individual in a position to 
                        assist another individual at risk of 
                        experiencing an opioid overdose.
    ``(b) Immunity From Liability.--
            ``(1) In general.--An individual who, in good faith and in 
        a timely manner--
                    ``(A) seeks medical assistance for another 
                individual who is experiencing a drug overdose, or
                    ``(B) seeks medical assistance for himself or 
                herself for a drug overdose, or is the subject of a 
                request for medical assistance described in 
                subparagraph (A),
        shall not be cited, arrested, prosecuted, criminally liable, or 
        subject to any sanction for a violation of a condition of 
        supervised release under section 404 of the Controlled 
        Substances Act for the possession or use of a controlled 
        substance, or under any other provision of Federal law 
        regulating the misuse of prescription drugs, as a result of 
        seeking such medical assistance.
            ``(2) Preemption.--This subsection preempts the laws of a 
        State or any political subdivision of a State to the extent 
        that such laws are inconsistent with this section, unless such 
        laws provide greater protection from liability.
            ``(3) Definitions.--In this section:
                    ``(A) The term `controlled substance' has the 
                meaning given the term in section 102 of the Controlled 
                Substances Act.
                    ``(B) The term `drug overdose' means an acute 
                condition resulting from or believed to be resulting 
                from the use of a controlled substance, which an 
                individual, who is not a health care professional, 
                would reasonably believe requires medical assistance.
                    ``(C) The term `prescription drug' means a drug 
                subject to section 503(b)(1) of the Federal Food, Drug, 
                and Cosmetic Act.
                    ``(D) The terms `seeks medical assistance' and 
                `seeking such medical assistance' include--
                            ``(i) reporting a drug or alcohol overdose 
                        or other medical emergency to a law enforcement 
                        authority, the 9-1-1 system, a poison control 
                        center, or a medical provider;
                            ``(ii) assisting another individual who is 
                        making a report described in clause (i); or
                            ``(iii) providing care to someone who is 
                        experiencing a drug or alcohol overdose or 
                        other medical emergency while awaiting the 
                        arrival of medical assistance.''.
    (b) Public Awareness Campaign.--The Secretary of Health and Human 
Services, in coordination with the Administrator of the Drug 
Enforcement Administration, shall carry out a campaign to increase 
public awareness of the limitations on civil and criminal liability 
established by section 249 of the Public Health Service Act, as added 
by subsection (a).

SEC. 306. REPORT ON OVERDOSE PREVENTION CENTERS.

    The Secretary of Health and Human Services shall enter into 
appropriate arrangements with the National Academies of Sciences, 
Engineering, and Medicine under which the Academies agree to--
            (1) not later than two years after the date of enactment of 
        this Act, submit to the Congress a report on overdose 
        prevention centers; and
            (2) include in such report--
                    (A) identification of barriers to operating 
                overdose prevention centers;
                    (B) a compilation of the data available to measure 
                effectiveness of overdose prevention centers on 
                reducing overdose deaths, and improving access to 
                medication for opioid use disorder and recovery 
                services;
                    (C) identification of best practices to promote 
                individual and community public health, provide 
                resources to individuals and families, improve access 
                to substance use disorder and behavioral health 
                services, and reduce stigma;
                    (D) recommendations for developing integrated care 
                settings inclusive of overdose prevention sites and 
                incorporating overdose prevention sites into referral 
                networks; and
                    (E) approaches to overdose prevention services that 
                may serve as effective strategies for recovery for 
                people using fentanyl.

SEC. 307. PRISONS AND SUBSTANCE USE DISORDER TREATMENT.

    (a) Prisons and Medication-Assisted Treatment.--The Director of the 
Bureau of Prisons, in collaboration with the Director of the Office of 
National Drug Control Policy, shall establish a program to offer to 
individuals in the custody of the Bureau of Prisons--
            (1) drugs that are approved by the Food and Drug 
        Administration for treatment of a substance use disorder;
            (2) counseling and other psychosocial treatments for the 
        treatment of substance use disorders; and
            (3) evidence-based withdrawal management services.
    (b) Residential Substance Abuse Treatment for State Prisoners.--
Section 1904(d) of title I of the Omnibus Crime Control and Safe 
Streets Act of 1968 (34 U.S.C. 10424(d)) is amended--
            (1) by striking ``means'' and inserting the following:
            ``(1) means'';
            (2) by striking the period at the end and inserting ``; 
        and''; and
            (3) by adding at the end the following:
            ``(2) includes any drug approved by the Food and Drug 
        Administration for the treatment of substance use disorder.''.
                                 <all>